discontinue sulfonylurea when starting glp-1 receptor agonist Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach | International Journal of Diabetes in Developing Countries Use of continuous glucose monitoring
Description
In addition to SGLT2 inhibitors and GLP-1 receptor agonists, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF [129-132]
A shortage of medicines containing GLP-1RAs has been affecting EU Member States since 2022
Additionally, patients often opt to discontinue this medication due to issues such as intolerance, loss of insurance coverage, affordability concerns, or pharmacy shortages
They demonstrate a favorable safety profile, allowing for co-administration with most other glucose-lowering medications, except vildagliptin
Identify documentation required by your insurance company
When the ERS intensity is too high or lasts for a long time, the endoplasmic reticulum cannot restore homeostasis
